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http://dx.doi.org/10.1016/j.ccell.2017.02.002SUMMARYWe identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and
relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and
showed that it increased CD3+ T cell/myeloma cell crosslinking, followed by CD4+/CD8+ T cell activation,
and secretion of interferon-g, granzyme B, and perforin. This effect is CD4 and CD8 T cell mediated.
EM801 induced, at nanomolar concentrations, myeloma cell death by autologous T cells in 34 of 43 bone
marrow aspirates, including those from high-risk patients and patients after multiple lines of treatment,
tumor regression in six of ninemice in amyeloma xenograft model, and depletion of BCMA+ cells in cynomol-
gus monkeys. Pharmacokinetics and pharmacodynamics indicate weekly intravenous/subcutaneous
administration.INTRODUCTION
Multiple myeloma is a malignant hematological disease charac-
terized by the accumulation of clonal plasma cells in the bone
marrow and associated clinical signs and symptoms, especially
those related to displacement of normal hematopoiesis and gen-
eration of osteolytic bone disease (Kyle and Rajkumar, 2004).
With more than 80,000 new diagnoses worldwide per year,
myeloma is the second most common hematological malig-Significance
Despite recent approval of multiple agents, the majority of mye
be treated effectively due to the toxicity of previous therapies.
our immunotherapeutic BCMA-T cell bispecific antibody app
active also in high-risk patients and non-cross-resistant with
side effects validating in vitro and in vivo target specificity t
and, together with a weekly administration schedule, for prolon
pound for multiple myeloma treatment, and our study gives th
396 Cancer Cell 31, 396–410, March 13, 2017 ª 2017 Elsevier Inc.nancy (Becker, 2011). Despite recent approval of multiple
agents, e.g., daratumumab, elotuzumab, carfilzomib, and poma-
lidomide (Lokhorst et al., 2015; Lonial et al., 2015; San Miguel
et al., 2013; Stewart et al., 2015), it is rare to eradicate all
myeloma cells and the vast majority of patients ultimately
become either refractory to all available compounds or can
no longer be treated effectively due to the toxicity of previous
treatments, and thus succumb to the disease. For this reason,
alternative immunotherapeutic options represent an attractiveloma patients ultimately become refractory or can no longer
Our study raises hope of overcoming this, at least in part, by
roach: EM801 shows promising single-agent activity, being
previous lines of treatment. Together with the spectrum of
his offers the opportunity for use in combination regimen
ged treatment. EM801 emerges therefore as attractive com-
e rationale for clinical testing.
strategy to cover this unmet medical need. One of the most
advanced options is the recruitment of innate immunity to kill
myeloma cells by immunoglobulin G (IgG) monoclonal anti-
bodies targeting antigens expressed on both normal as well
as malignant plasma cells (e.g., anti-CS1 or -CD38) (Deckert
et al., 2014; Lokhorst et al., 2015; Lonial et al., 2015). Another
approach is to (re)direct T cells toward myeloma cell killing.
This can be achieved via chimeric antigen receptor (CAR)- or
T cell receptor (TCR)-modified T cells. Both have shown preclin-
ical or early clinical activity, but require ex vivo engineering and
expansion of patient-specific T cells (Carpenter et al., 2013; Gar-
fall et al., 2015; Klebanoff et al., 2016; Rapoport et al., 2015; San
Miguel et al., 2015). Alternatively, T cell bispecific antibodies
(TCBs) that simultaneously bind a surface target on tumor cells
and an associated TCR chain (CD3 epsilon chain [CD3ε]) present
on all T cells have shown the capacity to induce a potent T cell-
mediated killing of cells carrying the target (Batlevi et al., 2016;
Lameris et al., 2014; Ramadoss et al., 2015; Staerz et al.,
1985), and are in principle applicable to all patients.
For our TCB approach, we selected as target the TNF receptor
superfamily member B cell maturation antigen (BCMA), which is
the receptor for themyeloma cell survival factors B cell activating
factor (BAFF) and a proliferation-inducing ligand. BCMA was
selected because it is essential for the survival of long-lived
bone marrow plasma cells (Moreaux et al., 2004; O’Connor
et al., 2004) and that its expression had previously been found
on primary myeloma cells in small cohorts of newly diagnosed
myeloma patients (Bellucci et al., 2005; Carpenter et al., 2013;
Claudio et al., 2002; Moreaux et al., 2004, 2009; Ng et al.,
2004; Novak et al., 2004; Tai et al., 2006, 2014).
The aims of our study were to assess BCMA as target for T cell
immunotherapy for myeloma and to generate and evaluate the
IgG-based BCMA-TCB EM801 for the treatment of multiple
myeloma.
RESULTS
Expression of BCMA
BCMA is expressed inmalignant plasma cells from all samples of
previously untreated or relapsed myeloma patients as assessed
by gene expression profiling (n = 712) and RNA sequencing (n =
263) (Figure 1A), including patients with highly proliferative dis-
ease or high-risk features according to chromosomal aberra-
tions or gene expression-based risk scores (Figure S1). Surface
BCMA antigen expression is found using multidimensional flow
cytometry on malignant plasma cells of all previously untreated
(n = 31) or relapsed myeloma patients (n = 12) (Figure 1B). The
BCMA antigen density on malignant (median of 1,479 specific
antibody-binding capacity [SABC] units; range, 42–14,055) and
normal (median of 673 SABC units; range, 189–1713) (Figures
1B and 1C) plasma cells was significantly (p < 0.001) higher
than on all other normal bone marrow cell subsets (median
of%65 SABC units; range, 0–213). In the latter subsets, BCMA
expression was absent (Figure 1A). Flow cytometry confirmed
the restricted expression of BCMAon both normal andmalignant
plasma cells (Figures 1B and 1C).
During B cell development, BCMA is expressed in normal
plasma cells and their highly proliferative precursors, polyclonal
plasmablasts, but absent in earlier stages such as pro- andpre-B cells, naive and memory B cells, as well as resting and
activated B cells (Figures 1A–1C).
BCMA is thus an attractive TCB target in both previously un-
treated and relapsed myeloma patients.
Constructing the BCMA-tcb EM801
EM801 is constructed as an asymmetric two-arm IgG1-based
human antibody based on a previously developed TCB platform
(Bacac et al., 2016), it binds bivalently to BCMA and monova-
lently to CD3ε (Figures 2A and S2A). To minimize unspecific
T cell activation in the absence of concomitant binding to
BCMA, binding to CD3ε on T cells is monovalent with a low affin-
ity of KD = 70–100 nM (surface plasmon resonance [SPR] mea-
surement), while binding to BCMA expressed on plasma cells
is of higher affinity (KD = 10 nM by SPR) and is bivalent for
an avidity effect to facilitate preferential binding to BCMA+
myeloma cells and in vivo tumor targeting (Figure S2B). Molecule
asymmetry is generated via a heterodimeric Fc region. Correct
association of the light chains of the antibody during production
is facilitated by introduction of a VH-VL crossover into the inter-
nal CD3ε binding Fab (Schaefer et al., 2011), whereas correct
heavy chain association is facilitated via the knob-into-hole tech-
nology (Ridgway et al., 1996). For extended elimination half-life,
EM801 carries a heterodimeric Fc region with intact FcRn
binding to enable at least once a week intravenous (i.v.) or sub-
cutaneous (s.c.) administration. To minimize the risk of infusion
reactions, binding to Fc gamma receptors expressed on innate
immune cells and to complement component (C1q), is abolished
by engineering of the heterodimeric Fc with P329G, L234A, and
L235Amutations (Schlothauer et al., 2016). EM801 does not bind
to TACI or BAFF-R, two receptors with high homology to BCMA
(Mackay and Ambrose, 2003) (data not shown). The intended
mechanism of action of BCMA-TCB is shown in Figure 2B.
EM801 BCMA-TCB can be easily produced with high purity
and was biophysically and biochemically stable with no ten-
dency for aggregation.
Mechanism of Action
Simultaneous binding of EM801 to CD3ε on T cells and BCMAon
myeloma cells resulted in a strong CD3+ T cell-tumor cell interac-
tion as visualized using immunofluorescence and electron scan-
ning microscopy (Figure 3A). In a concentration-dependent
manner, EM801 couples T cells and myeloma cells as measured
by atomic force microscopy with a median binding strength of
538 ± 210 pN (1.5- to 6-fold of control) for myeloma cell lines
(p < 0.001; n = 10) and 549 ± 149 pN (2- to 7-fold of control)
for primary myeloma cells (p < 0.001; n = 10) (Figure 3B). The
binding interaction between T cells and myeloma cells led to
TCR/CD3 crosslinking and activation of the CD3 downstream
signaling pathway (Figure 3C). T cell activation and increased
T cell function was observed by upregulation of CD69 and
CD25 expression, as well as release of granzyme B and proin-
flammatory cytokines, e.g., interferon-g (IFN-g), tumor necrosis
factor alpha (TNF-a), and interleukin-2 (IL-2) (Figures 3D and
3E). At 120 hr incubation, BCMA-TCB induced concentration-
dependent CD4+ and CD8+ T cell proliferation as measured
by carboxy-fluorescein succinimidyl ester (CFSE) dilution
(Figure 3F). Lack of need for TCR:major histocompatibility
complex(MHC) recognition through activation of the CD3Cancer Cell 31, 396–410, March 13, 2017 397
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Figure 1. Expression of B Cell Maturation Antigen in Normal and Malignant Plasma Cells as well as Other Cells of the Bone Marrow
Microenvironment
(A) The left panel shows gene expression profiling using DNA microarrays (206641_at) of monocytes (CD14, n = 5), T cells (CD3, n = 5), hematopoietic stem cells
(CD34, n = 5), mesenchymal stromal cells (MSC, n = 8), as well as in vitro differentiated osteoblasts (OB, n = 8) and osteoclasts (OC, n = 7), followed by normal
plasma cell precursors, i.e., memory B cells (MBC, n = 5) and in vitro generated polyclonal plasmablastic cells (PPC, n = 5), as well as normal bonemarrow plasma
cells (BMPC, n = 10), malignant plasma cells from patients with newly diagnosed multiple myeloma (MM, n = 630) and relapsed/refractory myeloma MM (MMR,
n = 82), and human myeloma cell lines (HMCL, n = 54). The dashed red line depicts the threshold for being predicted as expressed (above) or not expressed
(below) according to the PANP algorithm. The right panel shows confirmation using RNA sequencing of PPC (n = 4), MBC (n = 4), normal (n = 10) and malignant
plasma cells (n = 263), and cell lines (n = 19). BM, bone marrow.
(B) Illustrative results of flow cytometric detection of BCMA expression on normal and malignant plasma cells from a myeloma patient. APC, allophycocyanin.
(C) Specific antigen-binding capacity (SABC) ± SD per cell as determined by flow cytometry in normal (n = 25) and malignant (n = 35) plasma cells, as well as
HMCL (n = 7; left panel) compared with other bone marrow subsets. See also Figure S1.downstream signaling pathway induced by EM801 allowed us to
measure T cell-induced killing of myeloma cell lines in a 24 hr co-
culture assay with human peripheral blood mononuclear cells
(PBMCs) and myeloma cells at an effector:target (E:T) ratio of
10:1. Using EM801 as single agent, killing of NCI-H929, L363,
and RPMI 8226 myeloma cells was observed with median effec-
tive concentration (EC50) ranging from 7 to 35 pM as measured
by lactate dehydrogenase (LDH) release (Figure 3G). To prove
that the observed killing is dependent on CD3+ T cells and
furthermore can, in agreement with direct CD3 activation, be
performed by both CD4+ and CD8+ T cells, we exposed
myeloma cells plus EM801 with total, CD3-, CD4-, or CD8-
depleted peripheral blood leukocytes. In each experiment, equal398 Cancer Cell 31, 396–410, March 13, 2017numbers of leukocytes were used. Whereas minimal activity was
seen in CD3-depleted samples, both CD8+ and CD4+ T cells re-
maining in the leukocyte sample alone (i.e., in the CD4- and CD8-
depleted samples, respectively) were able to achieve similar
levels of activity during 48 hr exposure as the undepleted sample
(Figures 3H and S3).
Activity of EM801
In bone marrow aspirates (n = 19), increasing concentrations
of EM801 lead to higher T cell activation, with significantly
increased expression levels of CD69 (p < 0.001), CD25 (p <
0.001), and HLA-DR (p = 0.001) in both CD4+ and CD8+ T cells
compared with control TCB (binding to CD3ε, but not to
Figure 2. Structural Features and Assumed Mechanism of Action of the IgG-Based BCMA-TCB EM801
(A) EM801 is an asymmetric two-arm IgG1-based human antibody, bivalent to BCMA (KDz 10 nM) and monovalent to CD3ε (KDz 70–100 nM).
(B) Schematic depiction of the assumedmechanism of action of EM801: (1) binding to BCMA onmyeloma cells and CD3ε on T cells, thus coupling both cell types;
(2) T cell receptor/CD3 crosslinking leading to T cell activation and the release of cytokines (e.g., IFN-g, TNF-a); (3) cytolytic synapse formation and secretion of
cytolytic enzymes (e.g., granzyme B and perforin), and (4) the redirected killing of myeloma cells by autologous T cells (MHC class I independent). See also
Figure S2.BCMA) (Figures 4A, S4A, and S4B). EM801 significantly and
dose dependently induced secretion of cytokines and cytolytic
proteins, i.e., IFN-g from median 4 ± 194 pg/mL in the medium
control to 733 ± 1,069 pg/mL at 10 nM EM801 (p < 0.001; n =
24), granzyme B 42 ± 408 versus 644 ± 801 pg/mL (p < 0.001),
and perforin 225 ± 2,007 versus 672 ± 1,295 pg/mL (p < 0.01)
as measured by ELISA (Figure 4B). EM801 induced significant
primary myeloma cell death by autologous T cells in bone
marrow aspirates in 24/31 (77%) previously untreated and 10/
12 (83%) relapsed/refractory myeloma patients at concentra-
tions ranging from 10 pM to 30 nM (Figure 4C; Table 1). Activity
was also seen in samples from heavily pretreated patients as
shown for patient no. 21 (Figure 4D). The E:T ratio mirrored the
measured ratios as present in the bone marrow aspirates with
a median of 2.9 (range, 0.2–21) versus 1.0 (range, 0.03–4.3) in re-
sponding versus non-responding patients (p = 0.18), andmedian
SABC units were 1,267 (range, 42–6,400) versus 1,522 (range,
487–14,055) in responding versus non-responding patients
(p = 0.87) (Table 1). No toxicity was detected in cells of the
bone marrow microenvironment (Figures 4E and S4C).
In vivo antitumor activity was first studied in NCI-H929 s.c.
xenograft in human PBMC-transferred NOG mice. Treatment
was initiated when median tumor volume reached 287 ±
135 mm3 (similar for all groups; Table S1). At a dose of
2.6 nM/kg (0.5 mg/kg) of EM801, given once a week for 3 weeks,
tumor growth inhibition was already observed after the secondi.v. injection in six of nine animals, and the tumors regressed to
16 ± 3 mm3 on day 47 (Figure 5). Non-responding mice had
significantly higher tumor volumes (p = 0.048) above 375 mm3
at start of treatment (Table S1). An equimolar dose of control
TCB showed no effect (Figure 5).
To further investigate in vivo activity of our TCB in an autolo-
gous setting, we choose a cynomolgus monkey model. As in
humans, cynomolgus plasma cells express surface BCMA, but
unlike humans, the majority of cynomolgus peripheral blood
B cells also express BCMA (Figure S5A). The model thus allows
serial assessment of BCMA+ B cell depletion in peripheral blood
and BCMA+ plasma cell infiltration in the bonemarrow, as well as
the impact on IgG and IgM levels. The higher number of BCMA+
cells also mirrors more closely the situation in myeloma patients
regarding their typical tumor burden.
As the binding affinity of EM801 to cynomolgus BCMA is
approximately ten times lower than to human BCMA, and to
mirror as closely as possible the human situation, we con-
structed a surrogate BCMA-TCB2 with the same structure, the
same affinity to human and cynomolgus CD3, but comparably
high affinity with cynomolgus BCMA. We first confirmed cyno-
molgus BCMA+ cell lysis by BCMA-TCB2 in vitro (Figure S5B).
Next, a single i.v. injection of BCMA-TCB2 in the dose range
from 0.01 to 1 mg/kg already caused a decrease in BCMA+ cells
in blood 24 hr after injection and this was sustainable for up to
168 hr (Figure 6A). Blood B cell rebound associated withCancer Cell 31, 396–410, March 13, 2017 399
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B cell-depleting agents was observed 3 weeks post injection
(data not shown). In the bone marrow, a decrease in total B cells
and BCMA+ bone marrow cells was observed in all animals 96 hr
after injection of BCMA-TCB2 (Figures 6B and 6C). A dose-
dependent decrease in serum IgG levels up to 56.1% compared
with baseline was observed 168 hr post injection (Figure 6D). A
similar response was observed with serum IgM, indicating that
plasma cells are depleted by BCMA-TCB2. A transient increase
in activated CD8+ T cell absolute cell count was also detected in
the bone marrow of all animals 96 hr after injection; in agreement
with the observed induction of CD8 proliferation, CD25+CD8+
absolute T cell count returned to baseline level 3 weeks post in-
jection (Figure 6E). Similar results were observed for activated
CD25+CD4+ helper T cells in three of six animals, especially
when treated with the highest doses (Figure 6E). Themale animal
treatedwith 0.1mg/kg already had a high number of CD25+CD4+
cells pre-dose. A modest and transient increase in cytokine
release was measured 30 min after injection of BCMA-TCB2;
cytokine levels in plasma returned to baseline 8–24 hr after injec-
tion (Figure S5C).
Pharmacokinetic Studies in Monkeys and Mice
Figures 7A and 7B show the concentrations measured in serum
and bone marrow aspirates after 0.01, 0.1, and 1 mg/kg i.v. and
0.01 and 0.1 mg/kg s.c., respectively, in cynomolgus monkeys.
Pharmacokinetic (PK) parameters were determined by non-
compartmental analysis (Tables S2 and S3). PK is dose linear,
elimination half-life is approximately 4 days and bioavailability af-
ter s.c. dosing is above 90% (Table S3). BCMA-TCB concentra-
tions measured in bone marrow aspirates were similar to those
measured at the same time points in serum. These PK data sug-
gest the possibility for convenient i.v. or s.c. dosing once a week
or once every second week. PK results in immunodeficient mice
also suggest dose linearity and a long elimination half-life
(Figure 7C).
Observed Side Effects and Safety Aspects
In bone marrow aspirates from myeloma patients, no toxicity
was detected in cells of the microenvironment including B cell
subpopulations, T lymphocytes, or natural killer (NK) cells (Fig-
ures 4E and S4C). In cynomolgus monkeys, a single i.v. or s.c.
injection of BCMA-TCB2 up to 1 mg/kg was well tolerated in allFigure 3. Mechanism of Action of BCMA-TCB EM801
(A) Coupling of a CD3+ T cell to a BCMA+ myeloma cell by EM801 as assessed
(bottom). T cells are stained with anti-CD3-allophycocyanin (APC), myeloma cells
cells in scanning electron microscopy pictures is due to the drying process.
(B) The experimental setup followed bymeasured binding forces between T cells a
boxplot shows binding forces between T cells and myeloma cell lines (n = 10), th
patients (n = 10) compared with control. *p < 0.05, ***p < 0.001.
(C) Analysis of the CD3 downstream signaling pathway measured after of co-cult
increasing concentrations of EM801. RLU, relative luminescence units correspon
(D) T cell activation in both CD4+ and CD8+ T cells, as measured by flow cytometry
8226 with the indicated concentrations of EM801.
(E) Secretion of IFN-g, granzyme B, TNF-a, and IL-2 by T cells after co-culture o
(F) CD4+ and CD8+ T cell proliferation after incubation of BCMA+ RPMI 8226 my
EM801 as observed by CFSE dilution.
(G) Percentage of tumor cell lysis when co-culturing myeloma cell lines NCI-H92
(H) Percentage of myeloma cell lysis in the presence of total leukocytes versus
represent the SD. See also Figure S3.animals. A modest and transient increase in cytokine release
was observed, with plasma concentrations returning to baseline
levels within 24 hr (Figure S5C). A 4week toxicity trial in cynomol-
gus monkeys including, among other groups, a 1 mg/kg/week
group and a 2mg/kg/week group (three females and three males
in each group) at an average serum drug concentration, over the
4 weeks at 2 mg/kg/week, close to 100 nM, i.e., ten times higher
than therapeutic exposure, showed no pathological findings on
macroscopic and histopathological examination of all organs
(data not shown).
DISCUSSION
BCMA is an excellent immunotherapeutic target for myeloma for
several reasons. First, BCMA is expressed in all investigatedma-
lignant plasma cell samples in our large cohort of previously un-
treated or relapsed/refractory myeloma patients, in agreement
with earlier data obtained from myeloma cell lines and small pa-
tient cohorts (Bellucci et al., 2005; Carpenter et al., 2013; Claudio
et al., 2002; Moreaux et al., 2004, 2009; Ng et al., 2004; Novak
et al., 2004; Tai et al., 2006, 2014). BCMA is likewise expressed
in patients with adverse prognosis. Second, BCMA is essential
for the survival of normal long-lived bone marrow plasma cells
(O’Connor et al., 2004), making resistance by downregulation
during treatment unlikely, in contrast to other antigens such as
CD38 (Nijhof et al., 2015). Despite malignant plasma cells
showing a homogeneous pattern of positive BCMA expression
by flow cytometry, we cannot completely exclude the possibility
of a minor subclone expressing it at levels below those needed
for it to be a viable target for EM801, thus potentially giving
rise to disease progression. We could, however, show EM801
activity against cells expressing the lowest measured number
of cell surface BCMA molecules, 42, i.e., 35-fold lower than the
median of 1,479. This implies that our TCB is potentially able
to overcome low BCMA expression. Data with anti-BCMA
CAR-T cells also showed progression most frequently related
to the lack of persistence of BCMA+ CAR-T cells, not the emer-
gence of BCMA tumor cells (Ali et al., 2016). Taken together,
this makes a clonal escape scenario for BCMA-targeted treat-
ment unlikely. Third, in agreement with a previous report (Novak
et al., 2004), BCMA expression being absent in early B cell devel-
opment should allow for a rapid re-emergence of B cell immunityby scanning electron microscopy (top) and immunofluorescence microscopy
with anti-CD138-FITC and DAPI counterstaining. Scale bar, 5 mm. Shrinking of
ndmyeloma cells as assessed by atomic force microscopy are shown. The left
e right boxplot shows those between T cells and primary myeloma cells from
ure of GloResponse Jurkat NFAT-RE-luc2P and NCI-H929 myeloma cells and
ding to the intensity of luciferase expression downstream of CD3.
for the surface markers CD25 and CD69, after co-culture of PBMCs and RPMI
f PBMCs and RPMI 8226 upon treatment with EM801.
eloma cells compared with BCMA MKN45 control cells upon treatment with
9, L363, and RPMI 8226 with PBMCs in the presence of EM801.
CD3+ versus CD4+ versus CD8+ T lymphocyte-depleted samples. Error bars
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after cessation of anti-BCMA treatment. Fourth, the absence of
BCMA expression in other populations in the bone marrow indi-
cates a favorable toxicity profile.
As intended, EM801 effectively couples T cells and myeloma
cells leading into a 343 increased binding, followed by T cell
activation, proliferation, and myeloma cell killing. This implies
that crosslinking alone can induce myeloma cell killing, indepen-
dently of, or even overcoming, inhibitory mechanisms such as
loss of T cell repertoire or increased presence of accessory cells,
inhibiting immune response (Rabinovich et al., 2007) in terms of
primary myeloma cells, as well as of self-tolerance mechanisms
in place in cynomolgus monkeys. EM801 exerts its effect, as
TCB antibodies do in general, by redirecting and engaging
T cells via CD3, the common component of the TCR complex
in both CD4+ and CD8+ T cells, overcoming the need for antigen
recognition in MHC class II and I molecules from immune or tu-
mor cells, respectively. This explains why both CD4+ and CD8+
T cell rapidly become active and proliferate, and why each
subset alone is able to eliminate myeloma cells. The contribution
of both CD4+ and CD8+ T cell subsets to redirected lysis of tumor
cells has been reported, with a description of the mechanism of
action of, e.g., CD193CD3 or PSCA3CD3 TCBs (Brischwein
et al., 2006; Feldmann et al., 2012; Haas et al., 2009). These
studies have also shown that, similarly to our observations with
EM801, there is equal T cell lysis with only CD4+ or CD8+
T cells (Brischwein et al., 2006; Feldmann et al., 2012; Haas
et al., 2009). Whereas similar levels of T cell-induced killing in
CD4+- or CD8+-depleted samples compared with the full T cell
content may seem surprising, as the activity of the depleted
T cell fraction should be lacking, this should only be expected
in an experimental setting with an excess of target cells; with
the number of eliminated myeloma cells primarily being depen-
dent on the number of effector cells. The opposite is true for
our experiments with the number of effector cells exceeding
the number of myeloma cells (E:T ratios > 1:1, including the
CD4+- and CD8+-depleted samples). Under comparable condi-
tions, Feldmann et al. (2012) described that even a high increase
in T cells implies only limited effect on tumor cell lysis, i.e., 60%,
70%, or 80% average lysis at E:T ratios of 2:1, 5:1, and 10:1. In
other words, in the E:T range used in our experiments, and with
both CD4+ and CD8+ T cells contributing to a similar extent,
although with different kinetics to tumor cell lysis, a depletionFigure 4. T Cell Activation and Myeloma Cell Killing in Bone Marrow A
(A) T cell activation as measured by flow cytometry for the surface markers CD
samples).
(B) Secretion of IFN-g, granzyme B, and perforin by T cells using ELISA in bone
EM801. Boxplots summarizing the data are shown; see below for illustrative cas
(C) Killing of primary myeloma cells in bonemarrow aspirates ex vivo induced by E
regarding secretion of IFN-g, granzyme B, and perforin. Exemplary plots are sh
MMCs, myeloma cells.
(D)Myeloma cell killing with corresponding T cell activation regarding secretion of
a heavily pretreated patient (no. 21). Red arrows highlight the time point at which e
The blue line indicates the M-protein; units are shown on the left y axis (g/L). The o
on the right y axis (mg/L). Color bars indicate type and duration of different tre
methasone; CAD, cyclophosphamide, adriamycin, and dexamethasone; HDT, hi
dexamethasone; Pom/dex, pomalidomide and dexamethasone; pan-PIM inh., pa
and dexamethasone.
(E) Toxicity on cells of the bone marrow microenvironment is shown for the sam
marrow microenvironment. Error bars in each case represent the SD.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.of either population does not change the E:T ratio enough to
bear high impact on the number of eliminated myeloma cells.
In terms of activity, we first showed the ability of EM801 as a
single agent at low nanomolar concentrations to significantly
induce killing of primary myeloma cells by autologous T cells,
reaching 90% reduction of myeloma cells after 48 hr even in as-
pirates with a very low E:T ratio. We deliberately did not manip-
ulated E:T ratios in order to reproduce the high heterogeneity in
T cell numbers found in the bone marrow of myeloma patients,
and the demonstration of efficacy among patients with very
low E:T ratios warrants investigating if EM801 is clinically mean-
ingful in such patients. This is in agreement with previous obser-
vations using CAR-T cells (Carpenito et al., 2009; Kalos et al.,
2011). In the sense of a ‘‘serial killing,’’ each infused CAR-T cell
was assumed to have eradicatedmore than 1,000 leukemic cells
based on calculations using the estimated initial tumor burden
and the number of infused engineered T cells (Kalos et al.,
2011). To this end, the potential of each T cell to kill more than
one myeloma cell was validated by time-lapse microscopy.
Given that non-responders also showed T cell activation on the
background of limited time of exposure of primary myeloma
cells, we hypothesize that longer incubation might have turned
non-responders into responders. Based on our ex vivo data,
EM801 may thus overcome inhibitory immune mechanisms
such as T cell anergy.
In vivo activity of EM801 was demonstrated in two animal
models, i.e., the NOGmouse model with human myeloma xeno-
graft (allogeneic) and a cynomolgus monkey model. In the
former, given the high proliferation rate of the myeloma cell line
used being much higher than those observed in the vast majority
of myeloma patients (Hose et al., 2011), EM801 is thus able to
eradicate even highly proliferating myeloma cells. Mice not re-
sponding had a significantly higher initial tumor mass. As the
amount of myeloma cells which can be killed by CD3+ T cells
per time is limited (see above), and fast growth would especially
impact at higher initial numbers of myeloma cells, we see the
likely explanation that, in these cases, CD3+ T cells were not
able to cope with the number of myeloma cells. With the cyno-
molgus monkey model, we could show activity in an autologous
setting in vivo, i.e., reduction of the number of plasma cells in the
bone marrow as well as BCMA+ B cells in bone marrow and pe-
ripheral blood, including a decrease of serum IgG and IgM levels.spirates from Myeloma Patients Induced by EM801
69, CD25, and HLA-DR in both CD4+ and CD8+ T cells (n = 19 bone marrow
marrow samples (n = 24) upon treatment with the indicated concentrations of
es.
M801 in the presence of autologous T cells, and corresponding T cell activation
own for a newly diagnosed (no. 16, left) and a relapsed patient (no. 17, right).
IFN-g, granzymeB, and perforin (top four graphs) and clinical course (bottom) of
x vivo activity of EM801 in a bone marrow sample of the patient was analyzed.
range line indicates the value of the involved light chain (iFLC) with units shown
atment regimens. VCD, bortezomib (Velcade), cyclophosphamide, and dexa-
gh-dose chemotherapy; Len, lenalidomide consolidation; VD, bortezomib and
n-PIM kinase inhibitor; dex, dexamethasone; FVD, panobinostat, bortezomib,
e patients as in (C); measurements referred to medium control. BMME, bone
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Table 1. Activity of EM801 and Characteristics of Patients and Samples Included in the EM801 Ex Vivo Study
Patient
Sample No. Disease Stage SABCaBCMA E:T Ratio
b
% Myeloma Cell Lysis at 10 nM
at 48 hr (If Not Stated Otherwise)c
1 newly diagnosed 2,629 12.46 81.3
2 newly diagnosed 267 5.14 60.9
3 newly diagnosed 6,400 6.97 91.3
4 newly diagnosed 1,564 4.88 89.0
5 newly diagnosed 5,867 8.44 89.7
6 newly diagnosed 1,479 0.78 84.2
7 newly diagnosed 5,924 16.04 86.6
8 newly diagnosed 509 1.61 96.7
9 newly diagnosed 487 0.80 15.5
10 newly diagnosed 1,802 4.23 100.0
11 relapsed 14,055 0.03 9.0
12 newly diagnosed 5,129 3.07 100.0
13 newly diagnosed 4,138 4.25 15.4
14 newly diagnosed 42 1.16 86.8
15 newly diagnosed 3,252 0.17 83.0
16 newly diagnosed 1,013 0.49 92.6
17 relapsed 910 2.99 97.9
18 relapsed NA 0.22 90.6
19 newly diagnosed NA 6.43 100.0
20 newly diagnosed NA 9.35 100.0
21 relapsed NA 3.31 93.9
22 newly diagnosed NA 20.77 80.0
23 relapsed NA 2.15 95.6
24 newly diagnosed NA 4.99 80.7
25 newly diagnosed NA 11 55% annexin V positived,e
26 relapsed 4,479 0.5 45% annexin V positived,e
27 newly diagnosed 2,911 0.35 70.8d
28 newly diagnosed 1,267 0.54 92.6
29 relapsed 1,622 0.87 92.6d,e
30 relapsed 429 2.79 85.0f
31 newly diagnosed 1,684 2.4 26.6f
32 relapsed 383 0.41 84.0
33 newly diagnosed 1,602 1.03 65.5
34 newly diagnosed 799 1.35 38.0
35 newly diagnosed 204 2.95 25.9e
36 newly diagnosed 2,340 4.19 86.8
37 newly diagnosed 990 2.63 10.5f
38 relapsed 1,451 1.67 85.9
39 relapsed 1,608 0.55 98.5
40 newly diagnosed 246 0.18 38.2f
41 newly diagnosed 504 1.32 52.8f
42 relapsed 423 1 53.0
43 newly diagnosed 641 3.92 17.6
aSABC, specific antigen-binding capacity.
bE:T ratio, effector to target ratio.
cValues depict responding samples (i.e., statistically significant cell death); underlined values depict non-responding samples. Aminus sign depicts an
increase in cell number compared with the medium control. NA, not applicable.
dKilling at 3 nM.
eTwenty-four hour exposure.
fKilling at 30 nM.
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Figure 5. In Vivo Activity in the NCI-H929 s.c. Xenograft Human PBMC-Transferred NOG Mouse Model
Experimental setup (top) followed by in vivo activity of EM801 at 2.6 nM/kg (0.5 mg/kg) after once a week i.v. injection for 3 weeks (arrows) compared with a
control TCB antibody at equimolar dose (bottom left) versus vehicle control (bottom right) with nine mice per group. See also Table S1.Taken together, our data give convincing evidence for the activ-
ity of our TCB, thus warranting clinical testing.
Regarding the PKs, maintaining the Fc region leads to
extended elimination half-life and convenient weekly i.v. or
s.c. dosing intervals. This is, for example, in contrast to
BCMA-BiTE which requires continuous infusion via a pump
that patients have to carry for weeks of treatment (Hipp
et al., 2015). As an antibody, EM801 has several advantages
over CAR-T cell or TCR approaches. First, it is completely
eliminated from circulation within 1–2 months after cessation
of treatment, in contrast to the previously described long-
term persistence of engineered T cells (Kalos et al., 2011;
Rapoport et al., 2015). Second, the TCB approach and the
molecular format of EM801 is such that, in contrast, e.g., to
CAR-T cells, no patient-specific generation ex vivo is neces-
sary (Ali et al., 2016; Carpenter et al., 2013), allowing for its po-
tential use in almost all patients. In terms of side effects and
safety, histopathological assessment in cynomolgus monkeys
after repeated dosing did not show any pathological findings,
and observed cytokine release in these animals was modest
and transient.
In conclusion, EM801 emerges as an attractive non-cross-
resistant compound with high potential for use as a single
agent, in combination, or in long-term maintenance treatment
in multiple myeloma.
EXPERIMENTAL PROCEDURES
Patients, Healthy Donors, and Samples
Patients with previously untreated, therapy-requiring (n = 684) and relapsed
(n = 94) myeloma as well as healthy donors (n = 20) were included in the study,which was approved by the ethics committees of the University of Heidelberg
(no. 229/2003 and no. S-152/2010), as well as the University of Navarra (no.
115/2014) after written informed consent.
Normal bone marrow plasma cells and myeloma cells were purified
using anti-CD138 microbeads (Miltenyi Biotec), and aliquots of CD138+
malignant plasma cells were subjected to in situ fluorescence hybridization
(Hose et al., 2009; Neben et al., 2013; Seckinger et al., 2009). T cells for micro-
scopic analyses were purified using autoMACS Pro (Miltenyi Biotec). For
further cell populations and myeloma cell lines used, see the Supplemental
Information.
BCMA Expression
Gene Expression Profiling
Gene expression profiling was performed using U133 Plus 2.0 Arrays (Affyme-
trix) as published (Hose et al., 2011; Seckinger et al., 2009).
RNA Sequencing
Full-length, double-stranded cDNA was generated from 5 ng of total RNA and
amplified using the SMARTer Ultra Low RNA Kit (Illumina). Library preparation
was performed from 10 ng of fragmented cDNA using the NEBNext ChIP-Seq
Library Prep protocol (New England Biolabs). Libraries were sequenced on an
Illumina HiSeq 2000 with 2 3 50-bp paired-end reads.
Flow Cytometry
Cells were stained with anti-CD138-PE (Miltenyi Biotec), anti-CD38-FITC
(Becton Dickinson), and anti-BCMA-APC (provided by EngMab) for analysis
of the myeloma cell compartment. T cell analysis was performed using CD4-
FITC (Beckman Coulter), anti-CD45RA-APC, anti-CD45R0-PE (both from
SouthernBiotech), anti-CD28-PE, anti-CD25-PE, anti-CD95-APC, anti-CD3-
PerCP, and anti-CD8-APC-Cy7 (all from Becton Dickinson). Cells stained
with corresponding isotype antibodies were used as control. Analysis was
performed on a FACSAria or FACSCanto using FACSDiva software (Becton
Dickinson) and FlowJo version 3.0.7 (FlowJo, LLC).
Multidimensional flow cytometry immunophenotyping of bone marrow aspi-
rates was performed using an eight-color antibody combination and a direct
immunofluorescence stain-and-then-lyse technique: anti-CD45-V450 (Becton
Dickinson), anti-CD27-BV510 (BioLegend), anti-CD34-PerCP-Cy5.5 (BectonCancer Cell 31, 396–410, March 13, 2017 405
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Figure 6. In Vivo Activity in Cynomolgus Monkeys
(A and B) Total B cell numbers (BCMA+CD45+CD20+CD2CD16) from blood (A) and bone marrow (B) after single i.v. injection of 0.01, 0.1, and 1.0 mg/kg of
BCMA-TCB2. M, male; F, female, with three animals in each group.
(C) Numbers of bone marrow plasma cells (BCMA+CD20CD38hiCD2CD16). Green bars, females; blue bars, males.
(D) Serum IgG (left) and IgM levels (right) relative to baseline (%) in cynomolgus monkeys post single i.v. injection of 0.01, 0.1, or 1.0 mg/kg of BCMA-TCB2.
(E) Absolute cell counts of CD4+CD25+- (left) and CD8+CD25+-activated T cells (right) in bonemarrow post treatment with 0.01, 0.1, or 1.0 mg/kg of BCMA-TCB2.
Green bars, females; blue bars, males. See also Figure S5.
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Figure 7. Pharmacokinetics in Cynomolgus
Monkeys and Mice
(A) PK in cynomolgus monkeys upon i.v. adminis-
tration of BCMA-TCB2 at a single dose of 0.01, 0.1,
or 1.0 mg/kg. Concentrations measured in serum
(full lines) and bonemarrow aspirates (dotted lines).
Each vertical dotted line represents 1 week, the
green area shows the effective concentration
range of BCMA-TCB2 in bone marrow aspirates
from myeloma patients. F, female; M, male with
three animals in each group. PK parameters were
obtained by non-compartmental analysis.
(B) Concentrations measured in serum and bone
marrow aspirates after 0.01 and 0.1 mg/kg s.c.
(C) PK in mice after single i.v. dose with the indi-
cated concentrations of EM801. The horizontal
dotted line indicates the limit of quantification
levels. See also Tables S2 and S3.Dickinson), anti-CD19PE-Cy7 (Beckman Coulter), anti-BCMA-APC (provided
by EngMab), anti-CD38-FITC, anti-CD56-PE, and anti-CD138-APC.C750
(all from Cytognos). This combination allowed to evaluate surface expres-
sion of BCMA on malignant and normal plasma cells discriminated through
antigen underexpression (CD19, CD27, CD38, or CD45) or antigen overex-
pression (CD56), B cell precursors (CD19+CD34–/+CD38++), andmature B cells
(CD19+CD34CD38-/lo), T cells (CD19CD56FSCloSSClo), NK cells (CD19
CD56+FSCloSSClo), eosinophils (identified by FSC/SSC and autofluores-
cence pattern), neutrophils (CD45loSSChi), monocytes (CD45+SSCintCD38lo),
and erythroblasts (CD45SSClo). Cell acquisition was performed on a
FACSCanto II using FACSDiva software, and files were analyzed using Infinicyt
(Cytognos).CaBinding Capacity
BCMA density was assessed using QIFIKIT (Dako)
as per the manufacturer’s instructions. The SABC
was calculated as the number of BCMA antibodies
per cell after correction for background fluo-
rescence. Data analysis was performed using
FACSDiva software.
EM801Design, Production, andPurification
Generation of Fc-Containing 2+1
Asymmetric BCMA-TCB EM801
EM801 vectors were generated first. The IgG1-
derived bispecific molecules consisted of two anti-
gen-binding moieties capable of binding specif-
ically to two distinct antigenic determinants,
CD3ε and BCMA. The antigen-binding moieties
were Fab fragments composed of a heavy and light
chains, each comprising a variable and a constant
region. The Fab fragment binding to CD3ε was a
CrossFab fragment, wherein the variable domains
of the Fab heavy and light chains were exchanged.
The bispecificmolecule design wasmonovalent for
CD3ε and bivalent for BCMA, in which one Fab
fragment is fused to the N terminus of the inner
CrossFab (2+1) specific to CD3e. The bispecific
molecule contained an engineered silent Fc region.
Production
Molecules were produced by co-transfecting
HEK293-expressing Epstein-Barr virus nuclear an-
tigen (EBNA; American Type Culture Collection,
CRL-10852) growing in suspension with the
mammalian expression vectors using polymer-
based transfection. For preparation of 2+1
CrossFab-IgG constructs, cells were transfectedwith four corresponding expression vectors: (1) ‘‘vector Fc(knob),’’ (2) ‘‘vector
light chain,’’ (3) ‘‘vector light chain CrossFab,’’ and (4) ‘‘vector heavy chain
CrossFab,’’ using an optimal expression vector ratio.
Purification
EM801 was purified using standard purification methods including protein A
affinity chromatography resulting in high purity and monomer content.
Surface Plasmon Resonance
Affinity to humanBCMAwasmeasured using SPR (Supplemental Information).
Microscopy
The binding forces between myeloma cells and T cells were assessed by
atomic force microscopy; visualization of T cell-myeloma cell interaction wasncer Cell 31, 396–410, March 13, 2017 407
performed using fluorescence and scanning electron microscopy (see the
Supplemental Information).
T Cell Activation
Jurkat NFAT Reporter Cell Assay
Analysis of the CD3downstream signaling pathwaywasmeasured after 16 hr of
co-culture of GloResponse Jurkat NFAT-RE-luc2P (Promega) and NCI-H929
myeloma cells at an E:T ratio of 2.5:1 and increasing concentrations of
EM801, according to the manufacturer’s instructions. Relative luminescence
units, corresponding to the intensity of luciferase expression downstream of
CD3, was measured using a plate reader with glow-type luminescence reading
capabilities (Promega). Concentration-response curves and the EC50 values of
antibody responsewere fitted and calculated using Prism software (GraphPad).
Flow Cytometry
T cell activation was measured after 24–48 hr of co-culture of myeloma cell
lines with human PBMCs (E:T ratio = 10:1) or patient bone marrow aspirates
containing autologous T cells and myeloma cells with increasing concentra-
tions of EM801. Activation markers CD69, CD25, and HLA-DR (BD Biosci-
ences) were measured on CD4+ and CD8+ T cells.
T cell proliferation was measured using CFSE (Life Technologies) staining
(100 mM) and CFSE dilution analysis, after 5 days of co-culture of PBMCs
with RPMI 8226 myeloma target cells or MKN45 control cells (E:T ratio = 10:1).
ELISA
The amount of the secreted IFN-g (BD OptEIA ELISA sets, Becton Dickinson)
granzyme B, and perforin (both from Mabtech) in supernatants from bone
marrow cultures was quantified using ELISA and analyzed with an automated
plate reader (Tecan) using Magellan V2.22 software. Experiments were per-
formed in triplets.
Cytometric Bead Array
Cytokines/cytolytic enzymes, i.e., granzyme B, IFN-g, TNF-a, and IL-2 were
measured using a CBA Human Soluble Protein Flex Set (BD Biosciences), ac-
cording to the manufacturer’s instructions. Supernatants were collected from
48 hr co-cultures of PBMCs with myeloma cell lines as described below. Data
were acquired using FACSCanto II and EC50 values calculated using Prism
software (GraphPad).
EM801 Activity
Killing of Human Myeloma Cell Lines
Killing of humanmyeloma cell lines NCI-H929, L363, and RPMI 8226, express-
ing high, medium, and low levels of surface BCMA, respectively, was
measured by quantification of LDH release by dead cells into supernatant
(LDH Detection Kit, Roche Applied Science). In brief, unstimulated human
PBMCs were co-cultured with myeloma cell lines at an E:T ratio of 10:1 for
24–48 hr (37C, 5% CO2) together with graded concentrations of EM801 or
control TCB, i.e., 0.000128, 0.00064, 0.0032, 0.016, 0.08, 0.4, 2, and 10 nM
in triplicates. Maximal lysis of the target cells (=100%) was achieved by incu-
bation of target cells with 1% Triton X-100. Minimal lysis (=0%) refers to target
cells incubated with effector cells without EM801. The percentage of specific
cell lysis was calculated as [sample release  spontaneous release]/
[maximum release  spontaneous release] 3 100.
T Lymphocyte Depletion
Unstimulated peripheral blood leukocytes from two healthy donors were
co-cultured with NCI-H929 cells (5:1 ratio) for 48 hr under different conditions:
(1) total leukocytes; (2) leukocytes depleted of total CD3+ T lymphocytes plus
EM801 (50 pM); (3) leukocytes depleted of CD4+ T lymphocytes plus EM801
(50 pM); and (4) leukocytes depleted of CD8+ T lymphocytes plus EM801
(50 pM). For conditions 2, 3, and 4,wedepleted total or CD4andCD8T lympho-
cytesusingaFACSAria IIb (BDBiosciences). Ineachexperiment, equalnumbers
of leukocytes were used. The percentage of tumor cell lysis was measured
by [absolute numberof annexinV-negativemyelomacells/mL incondition1 –ab-
solute counts annexin V-negativemyelomacells cells/mL in conditions 2, 3, or 4)/
absolute counts annexin V-negativemyeloma cells/mL in condition 1]3100. The
absolute number of myeloma cells was determined using Perfect-Count Micro-
spheres (Cytognos) following the manufacturer instructions.
Primary Myeloma Cells Cultured together with Their Bone Marrow
Microenvironment
Primary myeloma cells cultured together with their bonemarrowmicroenviron-
ment (n = 24) were exposed to EM801 at graded concentrations as published408 Cancer Cell 31, 396–410, March 13, 2017previously (Seckinger et al., 2009). Compound exposure was performed once
on day 0 and cells were cultured for 48 hr. Each dose point was done in tripli-
cate. Data analysis was performed using FACSDiva software. Cell culture su-
pernatants were harvested for subsequent ELISA measurements.
Whole Bone Marrow
Whole bone marrow samples (n = 19) were cultured in RPMI 1640 medium
with 10% fetal bovine serum, 0.5% gentamicin, and 1% L-glutamine for
24 hr and/or 48 hr with increasing concentrations of EM801 (0.00003,
0.0003, 0.003, 0.03, 0.1, 0.3, 1, 3, 10, and 30 nM), control TCB (10, 30 nM),
or without any drug (control). After incubation, cells were lysed and stained
with antibodies against CD45, CD5, CD38, CD56, annexin V, CD19, BCMA,
and CD138 to measure cytotoxicity in myeloma cells and other bone marrow
subsets.
Xenograft Model
Animal housing and experimental procedures were realized according to the
French and European Regulations and the NRC Guide for the Care and Use
of Laboratory Animals. The animal facility is authorized by the French author-
ities (agreement no. B 21 231 011 EA). All procedures using animals were
submitted to the Animal Care and Use Committee Oncomet, agreed by French
authorities (CNREEA agreement no. 91). In vivo efficacy was studied in an s.c.
NCI-H929 xenograft model in human PBMC-transferred NOG (NOD.Cg-
PrkdcscidII2rgtm1Sug/JicTac, Taconic) mice. NOG mice aged 6–8 weeks
were injected s.c. with NCI-H929 cells (5 3 106 cells) and tumor volume
measured under blind conditions twice/week by caliper. Mice were injected
intraperitoneally with human PBMC (203 106 cells) 15 days after tumor cell in-
jection, then randomized into treatment and control groups using Vivo Man-
ager software (Biosystemes). Antibody treatment started 4 days after PBMC
transfer (i.e., 19 days after tumor cell injection), followed by i.v. injection of
EM801 (2.6 nM/kg), control TCB, or vehicle once a week for 3 weeks (n = 9
mice/group).
Cynomolgus Monkeys: Macaca fascicularis
The study protocol for the cynomolgusmonkeyswas approved by the local au-
thorities after review by the Animal Care and Use Committee of the AAALAC-
certified institution. All the animal procedures and ethical revision were per-
formed according to the current Italian legislation (Legislative Decree March
4th, 2014, no. 26) enforcing the 2010/63/UE Directive on the protection of an-
imals used for biomedical research and agreed by the Italian authorities. Due
to the low affinity to cynomolgus BCMA, EM801 is not an ideal molecule for
studies in cynomolgus monkeys. Therefore, we used surrogate BCMA-TCB2
with high affinity to cynomolgus BCMA. Effects were measured after i.v. injec-
tion of 0.01, 0.1, and 1.0 mg/kg of BCMA-TCB2. Absolute cell counts
for total B cells (CD45+CD20+CD2CD16), plasma cells (CD20CD38hi
CD2CD16CD27low/neg), as well as activated helper (CD25+CD45+CD2+
CD4+CD20CD16) and cytotoxic T cells (CD25+CD45+CD2+CD8+CD20
CD16) were calculated using flow cytometry (FACSCanto II) combined with
a hematology analyzer (ADVIA 120, Bayer). Serum IgG levels were measured
by ELISA (Life Diagnostics). Cytokine release was measured by multiplexed
bead-based immunoassay (Luminex).
PKs
Mouse
The study protocol was approved by the local authorities after review by the
Animal Care and Use Committee of the AAALAC-certified institution. The pro-
cedures and facilities comply with the requirements of Directive 2010/63/EU
from September 22, 2010, and subsequent amendments, as well as the na-
tional legislation defined in the German animal protection law ‘‘TierSchG (first
version July 24, 1972, actual version May 18, 2006 [BGB1. I S. 1206, 1313])’’ in
its current amended version. The experimental design was reviewed and
approved by the German authorities; project authorization registration no.
AZ 55.2-1-54-2532.2-7-13.
For details on PK studies in mice and monkeys, see the Supplemental
Information.
Statistical Analysis
See the Supplemental Information for details. For boxplots, the box expands
from the first/lower quartile (Q1), over the median to the third/upper quartile
(Q3). The inter-quartile range (IQR) is defined as IQR = Q1–Q3. The lower
whisker starts at Q1  1.5 3 IQR, if this is above the lowest data point,
otherwise it starts at the lowest data point; the upper whisker ends at Q3 +
1.5 3 IQR.
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